Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 14,342.90 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 14,202.00 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 13,117.20 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 12,172.90 millions
Regeneron Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 16,071.70 millions
REGN Revenue third quarter 2026 Y/Y Growth Comment
Regeneron Pharmaceuticals Inc achieved in the third quarter 2026, above Company average Revenue growth of 36.27% year on year, to $ 5,115.80 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 68 other companies have achieved higher Revenue growth. While Regeneron Pharmaceuticals Inc ' s Revenue rise of 36.27% ranks overall at the positon no. 642 in the third quarter 2026.
Regeneron Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 19.23%, to $ 5,115.80 millions, from $4,290.70 millions in the second quarter. REGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 539.
Regeneron Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 19.23%, to $ 5,115.80 millions, from $4,290.70 millions in the second quarter. REGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 539.
Regeneron Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year
Although Regeneron Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 30.71% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 18.59% year on year, from 9.29% in Jun 30 2026.
In the Healthcare sector 333 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1997, from total ranking in previous quarter at 2897.
Although Regeneron Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 30.71% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 18.59% year on year, from 9.29% in Jun 30 2026.
In the Healthcare sector 333 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1997, from total ranking in previous quarter at 2897.
About Regeneron Pharmaceuticals Inc Revenue Growth Rates (REGN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
60.74%